
Tilly’s (NYSE: TLYS) will be reporting its first-quarter financial results on May 29 after the market’s close. The general perception is that the sports apparel retailer had a lackluster start to the year. Analysts forecast a 50% decline in earnings to $0.02 per share on revenues of $128.73 million, which represents a modest year-over-year increase.
Revenues of the California-based company, which is specialized in apparels and footwear used in the action sports industry, stand to benefit from positive comparable store sales. Meanwhile, the bottom line might be negatively impacted by higher costs. In recent quarters, sales got a boost from the management’s efforts to ramp up the digital retail platform.
Related: Tilly’s Q4 2018 Earnings Conference Call Transcript
Looking Back
For the fourth quarter of 2018, Tilly’s had reported a 17.4% growth in adjusted earnings to $0.27 per share – which also exceeding the expectations – aided by a decline in income tax expense. However, the market reacted negatively to the report as the management’s first-quarter guidance fell short of expectations.
Sales have benefitted from the management’s efforts to ramp up the digital retail platform
At $170.6 million, revenues were up 3.8% in the fourth quarter. Comparable store net sales, which includes e-commerce sales, increased by 6.4%.
What Experts Say
On average, analysts covering the stock have given it buy rating, with an average price target of $16. The relatively low price of the stock makes it an investment option worth considering ahead of the earnings report.
Tilly’s shares have maintained a consistent downtrend over the past several months, after retreating from last year’s record high. The stock is currently trading 2% below the levels seen at the beginning of the year. In the past twelve months, it lost about 8%.
Most Popular
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent